Prognostication of the high-risk WM patient.
暂无分享,去创建一个
M. Dimopoulos | K. Konstantopoulos | T. Economopoulos | E. Kastritis | M. Gavriatopoulou | M. Kyrtsonis | A. Symeonidis | E. Terpos | K. Zervas | D. Gika | M. Voulgarelis | E. Stefanoudaki | P. Roussou | S. Delimpasi | E. Hadjiharissi | K. Tsatalas | N. Anagnostopoulos | A. Zomas | A. Sioni | E. Michalis | Z. Kartasis | Michael Michael | P. Repoussis | G. Kokkini | E. Vervesou
[1] M. Dimopoulos,et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). , 2009, Leukemia research.
[2] J. Crowley,et al. International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.
[3] Robert A Kyle,et al. Diagnosis and management of Waldenstrom's macroglobulinemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Lister,et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.